Oct 16, 2024, 14:54
Nelson Dusetti: Guiding treatment decisions for operable and metastatic patients with PDAC
Nelson Dusetti posted on X:
“We discuss here the dual resistance to mFOLFIRINOX and gemcitabine, the role of transcriptomic signatures in reducing toxicity and guiding treatment decisions for operable and metastatic patients reinforcing their potential for personalized treatment.
Nelson Dusetti, Scientific Director of the company Predicting Med (CSO) and Chair of TRANSLATE-IT CRCM. He is also research director at INSERM. He is the Head of the Department of Translational Research and Innovative Therapies at CRCM.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14